Quick Answer
LEXICON PHARMACEUTICALS, INC. reported Total Revenue of $49.80 million for fiscal year 2025.
LEXICON PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $49.80M +60.2% |
$31.08M +2481.5% |
$1.20M +766.2% |
$139.0K -53.4% |
$298.0K -98.8% |
$24.00M -92.5% |
| Revenue (ASC 606) | — | $6.00M +440.6% |
$1.11M | $0.00 | $0.00 -100.0% |
$23.40M -27.6% |
| Net Income | -$50.34M +74.9% |
-$200.40M -13.1% |
-$177.12M -73.7% |
-$101.94M -16.2% |
-$87.76M -49.8% |
-$58.57M -145.0% |
| Diluted EPS | -$0.14 +77.8% |
-$0.63 +21.3% |
-$0.80 -29.0% |
-$0.62 -3.3% |
-$0.60 -13.2% |
-$0.53 -145.7% |
| Total Assets | $184.99M -38.0% |
$298.42M +30.1% |
$229.43M +18.1% |
$194.30M +41.9% |
$136.91M -32.8% |
$203.79M -51.2% |
| Cash and Equivalents | $34.33M -48.5% |
$66.66M +196.7% |
$22.46M -51.5% |
$46.34M -27.7% |
$64.06M -49.3% |
$126.26M +249.6% |
| Long-Term Debt | $49.41M -50.7% |
$100.30M +0.8% |
$99.51M +104.8% |
$48.58M | $0.00 | $0.00 -100.0% |
| Stockholders Equity | $107.54M -26.3% |
$145.95M +56.8% |
$93.11M -20.5% |
$117.12M +3.1% |
$113.59M -27.4% |
$156.37M +33.5% |
| R&D Expense | $61.12M -27.7% |
$84.48M +43.5% |
$58.89M +11.5% |
$52.82M -4.1% |
$55.05M -64.2% |
$153.62M +67.1% |
| Operating Income | -$48.91M +75.2% |
-$197.12M -14.8% |
-$171.75M -70.5% |
-$100.76M -15.7% |
-$87.09M -82.2% |
-$47.80M -133.8% |
| Shares Outstanding | 365.85M +0.8% |
363.02M | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $14.18M | +710.4% | -50.9% |
| Revenue (ASC 606) | March 31, 2025 | $1.26M | +15.5% | -27.5% |
| Net Income | September 30, 2025 | -$12.77M | +80.3% | -492.7% |
| Diluted EPS | September 30, 2025 | -$0.04 | +77.8% | -500.0% |
| Total Assets | September 30, 2025 | $205.93M | -35.9% | -8.7% |
| Cash and Equivalents | September 30, 2025 | $49.66M | +43.7% | +132.4% |
| Long-Term Debt | September 30, 2025 | $56.51M | -43.4% | +0.7% |
| Stockholders Equity | September 30, 2025 | $120.16M | -32.7% | -7.2% |
| R&D Expense | September 30, 2025 | $18.76M | -27.2% | +19.1% |
| Operating Income | September 30, 2025 | -$12.19M | +80.9% | -426.2% |
| Shares Outstanding | September 30, 2025 | 365.78M | — | +0.8% |
- LEXICON PHARMACEUTICALS, INC. reported Total Revenue of $49.80 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +60.2% in Total Revenue compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $6.00 million for fiscal year 2024.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +440.6% in Revenue (ASC 606) compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Net Income of -$50.34 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +74.9% in Net Income compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Diluted EPS of $0.14 per share (loss) for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +77.8% in Diluted EPS compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Total Assets of $184.99 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -38.0% in Total Assets compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Cash and Equivalents of $34.33 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -48.5% in Cash and Equivalents compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Long-Term Debt of $49.41 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -50.7% in Long-Term Debt compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Stockholders Equity of $107.54 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -26.3% in Stockholders Equity compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported R&D Expense of $61.12 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -27.7% in R&D Expense compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Operating Income of -$48.91 million for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +75.2% in Operating Income compared to the prior fiscal year.
- LEXICON PHARMACEUTICALS, INC. reported Shares Outstanding of 365.85 million shares for fiscal year 2025.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +0.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: